Core growth is strong, but OSA must land
- Q1 2026 was strong enough for LivaNova to raise full-year revenue growth guidance to 7% to 8%.
- Cardiopulmonary is the main growth engine, helped by Essenz heart-lung machine placements and oxygenator demand.
- Epilepsy is improving after Medicare outpatient payments rose about 48% for new implants and 47% for end-of-service procedures.
- The aura6000 sleep apnea system has FDA approval, but the real test is the 2027 launch and reimbursement.
- A $365.6 million SNIA environmental liability is a real balance sheet overhang until the payment schedule is clear.
Great quarter, tougher proof ahead
LivaNova is executing well in its core business. In Q1 2026, Cardiopulmonary revenue grew 18.3% to $208.7 million, while Neuromodulation revenue grew 9.3% to $151.8 million. Management also raised full-year 2026 revenue growth guidance from 6% to 7% to 7% to 8%.
The bull case is simple. Essenz keeps taking share in heart-lung machines, oxygenators stay supply constrained in a way LivaNova can serve, and better Medicare payment helps VNS Therapy for epilepsy. If aura6000 launches on time in 2027 and gets paid well enough by insurers, sleep apnea could become a major new growth leg.
The bear case is also clear. The Essenz upgrade cycle may cool, oxygenator share gains may get harder, and aura6000 could be slow or expensive to launch. Neuromodulation segment income already fell in Q1 2026 because of higher OSA-related costs and contingent consideration expense.
The stock is not a clean bargain story. Investors already give LivaNova some credit for better execution and the sleep apnea option. Finn's view is balanced: strong performance, but only average growth visibility, financial health, valuation, and sentiment.
Machines first, disposables after
LivaNova makes money by selling medical devices to hospitals and doctors. In Cardiopulmonary, it sells heart-lung machines such as Essenz, then earns repeat revenue from disposable products like oxygenators used in procedures.
In Neuromodulation, LivaNova sells VNS Therapy systems for people with drug-resistant epilepsy. Revenue comes from new implants and replacement devices when older systems reach end of service.
The model works when procedure volumes grow, hospitals buy new platforms, supply is available, and reimbursement supports the cost of treatment. Price increases and market share gains have also helped recent results.
The next layer is pipeline-driven. Difficult-to-Treat Depression depends on a CMS coverage decision. Obstructive Sleep Apnea depends on turning the FDA-approved aura6000 system into a paid, scaled commercial product.
What LivaNova sells
Essenz heart-lung machines
Essenz is the key new Cardiopulmonary platform. Q1 growth was helped by more Essenz placements and strong demand across regions.
Oxygenators and cardiopulmonary disposables
These products are used during heart procedures and create repeat demand. Share gains have helped, but supply constraints are a watch item.
VNS Therapy for epilepsy
This is LivaNova's core Neuromodulation business for drug-resistant epilepsy. Medicare payment changes that began January 1, 2026 improve hospital economics.
aura6000 for obstructive sleep apnea
The FDA granted PMA approval on March 18, 2026. LivaNova plans a limited market release in the first half of 2027 and a broader launch in the second half of 2027.
VNS Therapy for Difficult-to-Treat Depression
DTD could expand VNS beyond epilepsy. The main gate is CMS national Medicare coverage, which remains uncertain.
Essenz data and analytics features
LivaNova is adding data capture and analytics to the Essenz platform. This can make the system more useful to hospitals, but it also adds execution and technology risk.
Two main revenue pools
Segment mix uses Q1 2026 net revenue: $208.7 million from Cardiopulmonary and $151.8 million from Neuromodulation. Cardiopulmonary is the larger segment, so any slowdown in Essenz or oxygenators would matter.
What could break the story
aura6000 launch disappoints
High impact · Medium oddsFDA approval lowered clinical and regulatory risk for obstructive sleep apnea. The next risk is commercial: LivaNova must build a sales team, train centers, set pricing, and secure workable payment. A slow 2027 ramp would weaken the biggest new growth option.
DTD coverage stays blocked
Medium impact · Medium oddsDifficult-to-Treat Depression uses VNS, but the business case depends on CMS national Medicare coverage. LivaNova started the reconsideration process in 2025. Without a favorable decision, DTD may remain a small or delayed opportunity.
Cardiopulmonary growth cools
High impact · Medium oddsCardiopulmonary has been the strongest part of the company, with Q1 2026 revenue up 18.3%. That pace may fade as the Essenz upgrade cycle matures. Oxygenator share gains also depend on supply and customer service.
Oxygenator supply bottlenecks
Medium impact · Medium oddsLivaNova has gained share partly because it executed well in a tight supply market. Third-party supplier issues could limit how much demand the company can fill. If customers cannot get product on time, share gains may stall.
SNIA payment drains capital
High impact · Medium oddsThe Italian Supreme Court decision turned SNIA into a recorded $365.6 million liability. The amount is now known, but timing and payment structure are not fully settled. A large near-term cash outflow could reduce flexibility for launches, R&D, or debt reduction.
Neuromodulation margins get squeezed
Medium impact · Medium oddsNeuromodulation revenue grew in Q1 2026, but segment income fell to $44.2 million from $52.4 million. Higher OSA-related R&D and contingent consideration expenses were key reasons. Pre-launch spending could pressure margins for several quarters.
In one breath
What does LivaNova do?
LivaNova is a medical device company. It sells Cardiopulmonary products used in heart procedures and Neuromodulation devices, mainly VNS Therapy for drug-resistant epilepsy.
Why does aura6000 matter for LivaNova stock?
aura6000 is LivaNova's FDA-approved system for obstructive sleep apnea. If the 2027 launch works and reimbursement is strong, it could add a new growth stream beyond the current core businesses.
What is the biggest risk for LivaNova?
The biggest company-specific risks are a slow aura6000 launch, a slowdown in Cardiopulmonary growth, and the $365.6 million SNIA environmental liability. Each could hurt growth, margins, or capital flexibility.
Is LivaNova mainly a heart device company or a brain device company?
It is both. In Q1 2026, Cardiopulmonary was the larger revenue segment, while Neuromodulation remained important through epilepsy and the OSA and DTD pipeline.